GSK is paying big bucks to Hutchmed to obtain a first-in-class oncology medicine. The asset in question is HMPL-A830, a preclinical KRAS-EGFR antibody conjugate that is expected to advance into clinical trials later this year.
The firm is paying $110 million up front and the overall amount involved in the deal could reach nearly $1.3 billion.
Under the agreement, the British pharmaceutical giant will receive global development and commercialization rights, while Hutchmed will retain rights in Mainland China, Hong Kong, Macau and Taiwan.
HMPL-A830 is designed to transport a KRAS inhibitor directly into tumors that express EGFR. The therapy simultaneously interferes with signaling from both EGFR and KRAS, an approach the companies said could improve efficacy, durability and tolerability.
The initial clinical program will focus on colorectal, pancreatic and lung cancers, which Hutchmed and GSK identified as the malignancies with the greatest numbers of patients whose tumors harbor KRAS alterations.
Hutchmed will lead the therapy through Phase 1 development before GSK assumes responsibility for subsequent research, development and commercialization, excluding the specified Asian territories.
Hesham Abdullah, M.D., SVP and Global Head of Oncology R&D at GSK, said the licensing deal underscores the company’s expanding position in oncology and its focus on bringing new cancer treatments to patients. He added that HMPL-A830’s dual KRAS-EGFR mechanism could offer a meaningful improvement over existing standards of care.
KRAS was historically considered a difficult target for drug developers, although several breakthroughs have emerged in recent years. One of the most prominent has been Bristol Myers Squibb’s Krazati, which has secured accelerated FDA approvals for certain patients with non-small cell lung cancer and colorectal cancer.
The future of Krazati’s accelerated approval in colorectal cancer has become less certain, however, after a confirmatory study failed to achieve its survival objectives earlier this summer.
EGFR expression is particularly common in subsets of non-small cell lung, head and neck, and brain cancers. Treatments targeting EGFR alterations include established medicines such as AstraZeneca’s Tagrisso and Iressa, as well as Tarceva, which is now marketed by Cheplapharm after previously being owned by Roche.
In other news for GSK, the firm reported encouraging Phase II results for its mRNA-based seasonal influenza vaccine at the OPTIONS XIII Conference for the Control of Influenza. In both younger and older adults, the candidate generated stronger immune responses against every influenza strain evaluated than the licensed standard-dose and high-dose inactivated vaccines, respectively, while remaining generally well tolerated. Based on these findings, GSK plans to launch a Phase III efficacy study in September 2026.
The upcoming study will mark the first Phase III trial of an mRNA influenza vaccine engineered to target both haemagglutinin (HA) and neuraminidase (NA), the two key surface antigens involved in the virus’s ability to attach to cells and spread. Existing licensed influenza vaccines mainly focus on HA, whereas GSK’s candidate has been developed to stimulate an immune response against NA as well. An expanding body of evidence indicates that adding NA to the target profile could potentially strengthen protection while reducing disease severity and limiting transmission.
Hutchmed has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an experimental KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC). The agreement gives GSK worldwide development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan.
The deal represents an important step for Hutchmed as it advances a new approach to precision oncology. HMPL-A830 is designed to combine targeted KRAS inhibition with EGFR targeting, potentially allowing the therapy to address cancer cells through two complementary mechanisms.
Hutchmed’s $1.295 Billion Agreement
Under the agreement, Hutchmed will receive an upfront payment of $110 million. Additional development, regulatory and commercial milestones could bring the total payments to as much as $1.295 billion, excluding royalties on net sales.
